Shanghai Allist Pharmaceuticals Co. Ltd. Class ASSE: 688578

"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD"Announcement on Voluntary Disclosure of the Acceptance of Marketing Application for a New Indication of Furmonertinib Mesilate Tablets

Sep 22, 2026 · Issued by Shanghai Allist Pharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Sep 22, 2026

Announcement on Voluntary Disclosure of the Acceptance of Marketing Application for a New Indication of Furmonertinib Mesilate Tablets

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Shanghai Allist Pharmaceuticals Co. Ltd. Class A

"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug IndustrySep 8
"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Implementation of Dividend Distribution for the First Half of 2026Aug 27
"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026Aug 20
"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026Jul 17

All Shanghai Allist Pharmaceuticals Co. Ltd. Class A news releases